AstraZeneca gets cozy with bloggers; Deborah Dunsire new CEO at EnVivo;

 @FiercePharma: Pharma, FDA still lag in post-marketing safety studies. Getting better, but large % unfinished--or not begun. Yesterday's story | Follow @FiercePharma

 @CarlyHFierce: NICE says 'no' to Celgene's Revlimid. Article | Follow @CarlyHFierce

> Regulators in Sweden have questioned why the European Medicines Agency would permit doctors to again use Bayer's Trasylol, which was suspended several years ago. Story

> Indian drugmakers Sun Pharma and Lupin have hit trading highs in India. Story

> Tris Pharma has launched dextroamphetamine sulfate oral solution, the first generic of the ADHD drug ProCentra. Release

> Deborah Dunsire, who just two months ago left Takeda's Millennium, has been tapped as the new CEO at EnVivo Pharmaceuticals. Story

Medical Device News

 @FierceMedDev: ICYM this week's M&A feature - Blockbusters and bloodlettings: A look at 2013's hot start. Special report | Follow @FierceMedDev

 @MarkHFierce: Only a few weeks left to nominate a company for this year's FMD Fierce 15. Submit your nomination | Follow @MarkHFierce

 @DamianFierce: Device outfit CVRx has raised $29.6M in a round led by NEA and J&J. Article | Follow @DamianFierce

> Report: Baxter's $4B bid for Gambro to win EU approval. More

> Stentys' self-apposing cardiac stent gains expanded CE mark indications. Item

> VisionCare discloses CMS coverage plan for implantable miniature telescope. Story

> Myriad targets Gene By Gene in second BRCA patent suit. Report

Biotech News

 @FierceBiotech: 2013 Biotech IPOs: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Deborah Dunsire makes quick leap from Millennium to fast-growing EnVivo. News | Follow @JohnCFierce

 @RyanMFierce: Alnylam Pharma spotlights more upbeat human data or gene-silencing drugs. Story | Follow @RyanMFierce

 @EmilyMFierce: Anti-leukemia compound could also treat common breast cancers. Story | Follow @EmilyMFierce

> Rockwell Medical shares spike on positive PhIII data. Item

> EU, pharma industry pledge $4.4B for R&D projects. Story

> Booming China poised to take a top position in global drug R&D. Article

Pharma Manufacturing News

 @EricPFierce: BioPlan says China, India losing luster for outsourced biopharmaceutical manufacturing. More | Follow @EricPFierce

> Wockhardt faces 2nd import alert. Report

> Sanofi's ImmuCyst available in next year, Alliance Pharma says. More

> Pfizer to invest $130M in 2 plants in Ireland. News

> Contract manufacturer Piramal also into development, cellphones. Story

Vaccines News

> Manufacturers prepare for resurgence of H7N9. News

> Robot eases kids' vaccination distress in study. More

> Novartis inks typhoid vax licensing deal with Biological E. Story

> U.K. mumps outbreak linked to waning MMR protection. Report

And Finally... AstraZeneca ($AZN) hosted what it labeled the "Inaugural Breast Cancer Blogger Summit," in which it invited a contingent of breast cancer bloggers to its offices in Fairfax, DE, to talk about what it is doing with breast cancer treatments, among other things. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.